Ali Riza Kural
Research Subjects
Ali Riza Kural has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aylin Altan Kus
Acibadem Univ, Atakent Hosp, Dept Radiol, Istanbul, Turkiye
1 shared publication - Banu Atalar
Department of Radiation Oncology, Acıbadem University Medical Faculty, Maslak Hospital, Istanbul, Turkiye
1 shared publication - Cavit Kerem Kayhan
Pathology Laboratory, Acıbadem Maslak Hospital, İstanbul, Turkey
1 shared publication - Deniz Alis
Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Radiology, Istanbul, Turkey
1 shared publication - Enis Ozyar
Department of Radiation Oncology, Acibadem MAA University School of Medicine, Istanbul, Turkey
1 shared publication - Ercan Karaarslan
Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Radiology, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 10 January 2022
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 106 (1) , 105
A Comparative Study of Multiparametric MRI Sequences in Measuring Prostate Cancer Index Lesion Volume
To compare the effectiveness of individual multiparametric prostate MRI (mpMRI) sequences-T2W, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC), and dynamic contrast-enhanced (DCE)-in assessing prostate cancer (PCa) index lesion volume using whole-mount pathology as the ground-truth; to assess the impact of an endorectal coil (ERC) on the measurements. We retrospectively enrolled 72 PCa patients who underwent 3T mpMRI with (n = 39) or without (n = 33) an ERC. A pathologist drew the index lesion borders on whole-mount pathology using planimetry (whole-mountvol). A radiologist drew the borders of the index lesion on each mpMRI sequence-T2Wvol, DWIvol, ADCvol, and DCEvol. Additionally, we calculated the maximum index lesion volume for each patient (maxMRIvol). The correlation and differences between mpMRI and whole-mount pathology in measuring the index lesion volume and the impact of an ERC were investigated. The median T2Wvol, DWIvol, ADCvol, DCEvol, and maxMRIvol were 0.68 cm3, 0.97 cm3, 0.98 cm3, 0.82 cm3, and 1.13 cm3. There were good positive correlations between whole-mountvol and mpMRI sequences. However, all mpMRI-derived volumes underestimated the median whole-mountvol volume of 1.97 cm3 (P ≤ 0.001), with T2Wvol having the largest volumetric underestimation while DWIvol and ADCvol having the smallest. The mean relative index lesion volume underestimations of maxMRIvol were 39.16% ± 32.58% and 7.65% ± 51.91% with and without an ERC (P = 0.002). T2Wvol, DWIvol, ADCvol, DCEvol, and maxMRIvol substantially underestimate PCa index lesion volume compared with whole-mount pathology, with T2Wvol having the largest volume underestimation. Additionally, using an ERC exacerbates the volume underestimation.
- 10 January 2022
- Published by Ubiquity Press, Ltd. in Journal of the Belgian Society of Radiology
- Vol. 106 (1) , 105
Open AccessA Comparative Study of Multiparametric MRI Sequences in Measuring Prostate Cancer Index Lesion Volume
To compare the effectiveness of individual multiparametric prostate MRI (mpMRI) sequences-T2W, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC), and dynamic contrast-enhanced (DCE)-in assessing prostate cancer (PCa) index lesion volume using whole-mount pathology as the ground-truth; to assess the impact of an endorectal coil (ERC) on the measurements. We retrospectively enrolled 72 PCa patients who underwent 3T mpMRI with (n = 39) or without (n = 33) an ERC. A pathologist drew the index lesion borders on whole-mount pathology using planimetry (whole-mountvol). A radiologist drew the borders of the index lesion on each mpMRI sequence-T2Wvol, DWIvol, ADCvol, and DCEvol. Additionally, we calculated the maximum index lesion volume for each patient (maxMRIvol). The correlation and differences between mpMRI and whole-mount pathology in measuring the index lesion volume and the impact of an ERC were investigated. The median T2Wvol, DWIvol, ADCvol, DCEvol, and maxMRIvol were 0.68 cm3, 0.97 cm3, 0.98 cm3, 0.82 cm3, and 1.13 cm3. There were good positive correlations between whole-mountvol and mpMRI sequences. However, all mpMRI-derived volumes underestimated the median whole-mountvol volume of 1.97 cm3 (P ≤ 0.001), with T2Wvol having the largest volumetric underestimation while DWIvol and ADCvol having the smallest. The mean relative index lesion volume underestimations of maxMRIvol were 39.16% ± 32.58% and 7.65% ± 51.91% with and without an ERC (P = 0.002). T2Wvol, DWIvol, ADCvol, DCEvol, and maxMRIvol substantially underestimate PCa index lesion volume compared with whole-mount pathology, with T2Wvol having the largest volume underestimation. Additionally, using an ERC exacerbates the volume underestimation.
- 29 October 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117) , 20200696
Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity
Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. Methods: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. Results: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. Conclusion: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. Advances in knowledge: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.
- 29 October 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117) , 20200696
Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity
Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. Methods: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. Results: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. Conclusion: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. Advances in knowledge: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.